Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
ABSTRACT Myelodysplastic syndrome with deletion of chromosome 5q (5q-syndrome) has a favorable prognosis and a low risk of transformation to acute myeloid leukemia, when treated with lenalidomide. Azacitidine leads to complete remission even as second-line therapy and in patients with clonal evoluti...
Guardado en:
Autores principales: | Palacios-Campos,Adriana, Gutierrez,Olga, Fabian-Morales,Eunice, Avilés,Alejandro, Candelaria,Myrna |
---|---|
Lenguaje: | English |
Publicado: |
Sociedad Médica de Santiago
2020
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000901357 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine
por: Carlo Pescia, et al.
Publicado: (2021) -
Managing myelodysplastic syndromes in very old patients: a teaching case report
por: Niscola P, et al.
Publicado: (2013) -
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie EK
Publicado: (2012) -
Therapy of Angiosarcoma with Thalidomide and Lenalidomide
por: M. Jules Mattes, et al.
Publicado: (2021) -
Comparative assessment of conventional chromosomal analysis and fluorescence in situ hybridization in the evaluation of suspected myelodysplastic syndromes: A single institution experience
por: Denyo Adjoa Zakhia, et al.
Publicado: (2019)